These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35857872)

  • 1. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
    Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth.
    Zhao B; Zou J; Wang H; Johannsen E; Peng CW; Quackenbush J; Mar JC; Morton CC; Freedman ML; Blacklow SC; Aster JC; Bernstein BE; Kieff E
    Proc Natl Acad Sci U S A; 2011 Sep; 108(36):14902-7. PubMed ID: 21746931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EBF1 binds to EBNA2 and promotes the assembly of EBNA2 chromatin complexes in B cells.
    Glaser LV; Rieger S; Thumann S; Beer S; Kuklik-Roos C; Martin DE; Maier KC; Harth-Hertle ML; Grüning B; Backofen R; Krebs S; Blum H; Zimmer R; Erhard F; Kempkes B
    PLoS Pathog; 2017 Oct; 13(10):e1006664. PubMed ID: 28968461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
    Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.
    Schlee M; Krug T; Gires O; Zeidler R; Hammerschmidt W; Mailhammer R; Laux G; Sauer G; Lovric J; Bornkamm GW
    J Virol; 2004 Apr; 78(8):3941-52. PubMed ID: 15047810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.
    Bristol JA; Nelson SE; Ohashi M; Casco A; Hayes M; Ranheim EA; Pawelski AS; Singh DR; Hodson DJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2024 Apr; 20(4):e1012132. PubMed ID: 38620028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
    Pich D; Mrozek-Gorska P; Bouvet M; Sugimoto A; Akidil E; Grundhoff A; Hamperl S; Ling PD; Hammerschmidt W
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
    Rowe M; Raithatha S; Shannon-Lowe C
    J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.
    Wang C; Zhou H; Xue Y; Liang J; Narita Y; Gerdt C; Zheng AY; Jiang R; Trudeau S; Peng CW; Gewurz BE; Zhao B
    J Virol; 2018 May; 92(9):. PubMed ID: 29467311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shared and distinct interactions of type 1 and type 2 Epstein-Barr Nuclear Antigen 2 with the human genome.
    Viel KCMF; Parameswaran S; Donmez OA; Forney CR; Hass MR; Yin C; Jones SH; Prosser HK; Diouf AA; Gittens OE; Edsall LE; Chen X; Rowden H; Dunn KA; Guo R; VonHandorf A; Leong MML; Ernst K; Kaufman KM; Lawson LP; Gewurz B; Zhao B; Kottyan LC; Weirauch MT
    BMC Genomics; 2024 Mar; 25(1):273. PubMed ID: 38475709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nuclear chaperone nucleophosmin escorts an Epstein-Barr Virus nuclear antigen to establish transcriptional cascades for latent infection in human B cells.
    Liu CD; Chen YL; Min YL; Zhao B; Cheng CP; Kang MS; Chiu SJ; Kieff E; Peng CW
    PLoS Pathog; 2012; 8(12):e1003084. PubMed ID: 23271972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes.
    Su C; Lu F; Soldan SS; Lamontagne RJ; Tang HY; Napoletani G; Farrell PJ; Tempera I; Kossenkov AV; Lieberman PM
    PLoS Pathog; 2021 Aug; 17(8):e1009834. PubMed ID: 34352044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.
    Faumont N; Durand-Panteix S; Schlee M; Grömminger S; Schuhmacher M; Hölzel M; Laux G; Mailhammer R; Rosenwald A; Staudt LM; Bornkamm GW; Feuillard J
    J Virol; 2009 May; 83(10):5014-27. PubMed ID: 19264782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells.
    Kohlhof H; Hampel F; Hoffmann R; Burtscher H; Weidle UH; Hölzel M; Eick D; Zimber-Strobl U; Strobl LJ
    Blood; 2009 May; 113(22):5506-15. PubMed ID: 19339697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
    Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
    J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
    Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased association between Epstein-Barr virus EBNA2 from type 2 strains and the transcriptional repressor BS69 restricts EBNA2 activity.
    Ponnusamy R; Khatri R; Correia PB; Wood CD; Mancini EJ; Farrell PJ; West MJ
    PLoS Pathog; 2019 Jul; 15(7):e1007458. PubMed ID: 31283782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NP9 protein encoded by the human endogenous retrovirus HERV-K(HML-2) negatively regulates gene activation of the Epstein-Barr virus nuclear antigen 2 (EBNA2).
    Gross H; Barth S; Pfuhl T; Willnecker V; Spurk A; Gurtsevitch V; Sauter M; Hu B; Noessner E; Mueller-Lantzsch N; Kremmer E; Grässer FA
    Int J Cancer; 2011 Sep; 129(5):1105-15. PubMed ID: 21710493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBNA2 and Its Coactivator EBNA-LP.
    Kempkes B; Ling PD
    Curr Top Microbiol Immunol; 2015; 391():35-59. PubMed ID: 26428371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus subverts mevalonate and fatty acid pathways to promote infected B-cell proliferation and survival.
    Wang LW; Wang Z; Ersing I; Nobre L; Guo R; Jiang S; Trudeau S; Zhao B; Weekes MP; Gewurz BE
    PLoS Pathog; 2019 Sep; 15(9):e1008030. PubMed ID: 31518366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.